



Figure S1. FOXO3 might be a downstream target of SIRT2 and contributes to cisplatin sensitivity in ovarian cancer. FOXO3 expression was detected in A2780/S and A2780/CP cells with cisplatin treatment (2 μ M) for 24 and 48 h (Figure S1A). FOXO3 expression was detected in A2780/S and A2780/CP cells with cisplatin treatment in different concentrations (Figure S1B). FOXO3 expression in cytoplasm and nucleus level was detected in A2780/S and A2780/CP cells with cisplatin treatment (2 μ M) for 24 and 48 h (Figure S1C). Results are shown as mean \pm SEM (* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$).